Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868838 | 1.00 | DRD4 (0.37) | DRD4DRD3SIGMAR1TMEM97HSD11B1 | |
| SCHEMBL4879527 | 0.92 | ERBB2 (0.36) | DRD4DRD3SIGMAR1TMEM97HSD11B1 | |
| SCHEMBL4879524 | 0.92 | ERBB2 (0.36) | DRD4DRD3SIGMAR1TMEM97HSD11B1 | |
| SCHEMBL4877782 | 0.91 | MAPK14 (0.38) | DRD4DRD3SIGMAR1TMEM97HSD11B1 | |
| SCHEMBL4877778 | 0.91 | MAPK14 (0.38) | DRD4DRD3SIGMAR1TMEM97HSD11B1 | |
| SCHEMBL4868318 | 0.90 | HSD11B1 (0.41) | HSD11B1MAPK14P2RX7 | |
| SCHEMBL4868322 | 0.90 | HSD11B1 (0.41) | HSD11B1MAPK14P2RX7 | |
| SCHEMBL4879571 | 0.89 | HSD11B1 (0.35) | HSD11B1HTR2AHTR2CMAPK14GAA | |
| SCHEMBL4874582 | 0.89 | MAPK14 (0.39) | SIGMAR1HSD11B1HTR2AHTR2CMAPK14 | |
| SCHEMBL4874578 | 0.89 | MAPK14 (0.39) | SIGMAR1HSD11B1HTR2AHTR2CMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | DRD4 4800/4885DRD3 4564/4885SIGMAR1 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.